B · Normal
[AbbVie’s Upatinib Extended-Release Tablets Approved for Non-Segmental Vitiligo in China] On November 13, AbbVie announced that China’s National Medical Products Administration (NMPA) has approved Ruifu (upatinib extended-release tablets, 15 mg, once daily) for the treatment of non-segmental vitiligo (NSV) in adults and adolescents aged 12 years and above who are suitable for systemic treatment. This approval makes Ruifu the first and only systemic drug approved for the treatment of non-segmental vitiligo in China.
Comments